197 results
8-K
EX-99.1
RZLT
Rezolute, Inc.
19 Sep 24
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
4:09pm
Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which
8-K
EX-99.1
ajk6mtzl31mbf
9 Sep 24
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
7:30am
8-K
EX-99.2
3enlyz81m jhdl
5 Aug 24
Second rare disease program with RZ358 in Phase 3 development
7:30am
8-K
EX-99.1
7bqciuw 3i5jh
5 Aug 24
Second rare disease program with RZ358 in Phase 3 development
7:30am
8-K
EX-99.1
qpn2 1owrwg
28 Jun 24
Regulation FD Disclosure
5:15pm
8-K
EX-99.1
ae15sy eiau
27 Jun 24
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
8:01am
8-K
EX-1.1
26oa9zw5f
14 Jun 24
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
4:51pm
8-K
EX-99.1
c75llxqc6t w5oeirbf
14 Jun 24
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
4:51pm
424B5
6rgn39joq9h72
14 Jun 24
Prospectus supplement for primary offering
4:49pm
424B5
47lzb dfauwnyi
13 Jun 24
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
moekza1n4dopk
24 May 24
Regulation FD Disclosure
2:37pm
8-K
EX-99.1
pohi2 33hh698ye
15 May 24
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
4:13pm
8-K
EX-99.1
wxtb8a
25 Apr 24
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
5:23pm